Vaccinex, Inc.

Vaccinex, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted biologic therapies for serious diseases with unmet medical needs, such as neurodegenerative diseases, cancer, and autoimmune disorders. The company identifies itself as a leader in semaphorin 4D (SEMA4D) biology and states it is the only company targeting SEMA4D for potential treatment of these conditions. SEMA4D is an extracellular signaling molecule that regulates immune and inflammatory cell activity. Vaccinex has utilized its SEMA4D antibody platform and knowledge of SEMA4D biology to develop its lead product candidate, pepinemab, an antibody. The company is primarily focused on developing pepinemab for Alzheimer's disease, and as resources permit, also for head and neck cancer and pancreatic cancer. Third-party investigators have also studied pepinemab in clinical trials for breast cancer and in "window of opportunity" studies for other indications, including melanoma. Vaccinex has developed multiple proprietary platform technologies and product candidates. Its SEMA4D antibody platform includes pepinemab, which is in clinical development for Alzheimer's disease, head and neck cancer, pancreatic cancer, and breast cancer, through company efforts or investigator-sponsored trials. An additional product candidate, VX5, is in an earlier stage of development and was selected using the ActivMAb platform.